Amylyx Pharmaceuticals, Inc. (AMLX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

-35M 0 35M 70M 105M Q1 '24: 88.6M Q2 '24: -1M Q3 '24: 416K Q4 '24: -665K Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Gross Profit Quarterly

-30M 0 30M 60M 90M Q1 '24: 82.7M Q2 '24: -1M Q3 '24: 416K Q4 '24: -665K Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '24: -75.7M Q4 '24: -40.7M Q1 '25: -37.8M Q2 '25: -42.9M Q3 '25: -36M Q4 '25: -36.6M Q1 '26: -43.8M Q2 '26: -45.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '24: -72.7M Q4 '24: -37.5M Q1 '25: -35.9M Q2 '25: -41.4M Q3 '25: -34.4M Q4 '25: -33M Q1 '26: -41.3M Q2 '26: -43.4M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 2.5M 5M 7.5M Q1 '24: 5.9M Q2 '24: 8K Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '24: -41.6M Q4 '24: -59M Q1 '25: -39.8M Q2 '25: -25.2M Q3 '25: -30.4M Q4 '25: -27.9M Q1 '26: -36.9M Q2 '26: -31.4M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q1 '24: -556K Q2 '24: -66.7M Q3 '24: -41.6M Q4 '24: -59M Q1 '25: -39.8M Q2 '25: -25.3M Q3 '25: -30.4M Q4 '25: -28M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q1 '24: 67.9M Q2 '24: 68M Q3 '24: 68.1M Q1 '25: 85.7M Q2 '25: 89.1M Q3 '25: 93.3M Q1 '26: 110.6M Q2 '26: 111.2M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '24: -3.82 Q4 '24: -4.43 Q1 '25: -3.10 Q2 '25: -2.49 Q3 '25: -1.79 Q4 '25: -1.53 Q1 '26: -1.48 Q2 '26: -1.41 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.